109 related articles for article (PubMed ID: 21280229)
1. BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution.
Briard E; Orain D; Beerli C; Billich A; Streiff M; Bigaud M; Auberson YP
ChemMedChem; 2011 Apr; 6(4):667-77. PubMed ID: 21280229
[TBL] [Abstract][Full Text] [Related]
2. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod).
Briard E; Rudolph B; Desrayaud S; Krauser JA; Auberson YP
ChemMedChem; 2015 Jun; 10(6):1008-18. PubMed ID: 25924727
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
4. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Kipp M; Amor S
Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of fluorinated fingolimod (FTY720) analogues for sphingosine-1-phosphate receptor molecular imaging by positron emission tomography.
Shaikh RS; Schilson SS; Wagner S; Hermann S; Keul P; Levkau B; Schäfers M; Haufe G
J Med Chem; 2015 Apr; 58(8):3471-84. PubMed ID: 25826109
[TBL] [Abstract][Full Text] [Related]
6. A dual fluorinated and iodinated radiotracer for PET and SPECT imaging of β-amyloid plaques in the brain.
Watanabe H; Ono M; Kimura H; Kagawa S; Nishii R; Fuchigami T; Haratake M; Nakayama M; Saji H
Bioorg Med Chem Lett; 2011 Nov; 21(21):6519-22. PubMed ID: 21920750
[TBL] [Abstract][Full Text] [Related]
7. Predicting PET-derived myelin content from multisequence MRI for individual longitudinal analysis in multiple sclerosis.
Wei W; Poirion E; Bodini B; Tonietto M; Durrleman S; Colliot O; Stankoff B; Ayache N
Neuroimage; 2020 Dec; 223():117308. PubMed ID: 32889117
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies?
Köhne A; Stettner M; Jangouk P; Dehmel T; Hartung HP; Lehmann HC; Kieseier BC
Arch Neurol; 2012 Oct; 69(10):1280-9. PubMed ID: 22751954
[TBL] [Abstract][Full Text] [Related]
9. Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors.
Cui QL; Fang J; Kennedy TE; Almazan G; Antel JP
Glia; 2014 Aug; 62(8):1361-75. PubMed ID: 24810969
[TBL] [Abstract][Full Text] [Related]
10. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
11. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
12. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
13. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of radioiodinated 3-phenylcoumarin derivatives targeting myelin in multiple sclerosis.
Watanabe H; Sakai S; Iikuni S; Shimizu Y; Shirakawa H; Kaneko S; Ono M
Bioorg Med Chem Lett; 2020 Dec; 30(24):127562. PubMed ID: 32971260
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, radiosynthesis and biochemical evaluation of fluorinated analogues of sphingosine-1-phosphate receptor 3 specific antagonists using PET.
Prasad VP; Wagner S; Keul P; Hermann S; Levkau B; Schäfers M; Haufe G
Bioorg Med Chem; 2024 Apr; 104():117697. PubMed ID: 38599005
[TBL] [Abstract][Full Text] [Related]
16. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
17. FTY720 for cancer therapy (Review).
Zhang L; Wang HD; Ji XJ; Cong ZX; Zhu JH; Zhou Y
Oncol Rep; 2013 Dec; 30(6):2571-8. PubMed ID: 24100923
[TBL] [Abstract][Full Text] [Related]
18. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
19. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of fluorinated analogues of sphingosine-1-phosphate antagonists as potential radiotracers for molecular imaging using positron emission tomography.
Prasad VP; Wagner S; Keul P; Hermann S; Levkau B; Schäfers M; Haufe G
Bioorg Med Chem; 2014 Oct; 22(19):5168-81. PubMed ID: 25216968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
